Towards Healthcare
Inhaled Therapy in Respiratory Disease Market to Lead USD 16.22 Bn by 2034

Inhaled Therapy in Respiratory Disease Market Smart Inhaler Trend

The inhaled therapy in respiratory disease market is valued at USD 11.98 billion in 2025 and expected to reach USD 16.22 billion by 2034 at 3.44% CAGR. Dominant segments include bronchodilators (28%), MDIs (35%), COPD (38%), retail pharmacies (60%), and inhaled biologics growing fastest. North America holds 42% share, Asia Pacific fastest-growing. The report covers top players like GSK, AstraZeneca, Teva, Novartis, Chiesi, competitive landscape, trade, value chain, manufacturers, and suppliers.

Content

  • Last Updated: 14 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The inhaled therapy in respiratory disease market stands at USD 11.98 billion in 2025 and is expected to reach USD 16.22 billion by 2034, growing at a CAGR of 3.44% from 2024 to 2034.

North America is currently leading the inhaled therapy in respiratory disease market share 42% due to the growing respiratory disease burden.

Some key players include Chiesi Farmaceutici, Cipla, Viatris/Mylan, and Insmed.

Key trends include growing acquisition and collaboration to promote the use and launch of various inhaled therapies for respiratory diseases.

Rising COPD/asthma prevalence is the factor that drives the market growth.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions